Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$28.80

-0.25 (-0.86%)

16:09
02/13/18
02/13
16:09
02/13/18
16:09

Exelixis says cabozantinib study showed 'encouraging' efficacy

Exelixis announced results from a phase 2 investigator-sponsored trial of cabozantinib for the first-line treatment of metastatic radioiodine-refractory differentiated thyroid carcinoma. The results were the subject of a news briefing that took place earlier today and will be presented during an oral session on February 16 starting at 1:30 p.m. MT at the 2018 Multidisciplinary Head and Neck Cancers Symposium, which is being held in Scottsdale, Arizona, February 15-17, 2018. Patients with metastatic, RAI-refractory DTC were enrolled in this single-arm, open-label trial, and were administered oral cabozantinib 60 mg once daily. The primary endpoint of the trial is objective response rate. Among the 35 patients who were evaluable for response, partial response was achieved by 54 percent of patients, and stable disease was reported in 43 percent of patients per RECIST 1.1. All but one evaluated patient experienced a decrease in tumor target lesions. Secondary endpoints of the trial include progression-free survival, time to progression, duration of response and clinical benefit rate defined as the number of patients achieving an objective response or stable disease for at least 6 months. The CBR at six months was 80 percent. With a median follow up for the study of 35 weeks the median PFS has not been reached. The median TTP among those patients who progressed was 35 weeks. "While many patients with differentiated thyroid cancer can be treated successfully with radioiodine, there are very few options for those patients whose tumors have become resistant to treatment," said Marcia Brose, M.D., Ph.D., Associate Professor of Otorhinolaryngology: Head and Neck Surgery and Director of the Center for Rare Cancers at the Abramson Cancer Center of the University of Pennsylvania, and principal investigator of the trial. "These findings suggest that cabozantinib, which showed encouraging efficacy and a manageable safety profile in this phase 2 trial, may be a promising treatment option for this patient population and warrants further evaluation."

  • 14

    Feb

  • 15

    Feb

EXEL Exelixis
$28.80

-0.25 (-0.86%)

10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
01/04/18
PIPR
01/04/18
NO CHANGE
Target $37
PIPR
Overweight
Piper ups Exelixis target to $37, names a top pick for 2018
Piper Jaffray analyst Edward Tenthoff names Exelixis a top pick for 2018 and raised his price target for the shares to $37 from $33. The analyst expects Cabometyx growth from driven label expansion and is positive into the Phase III Cotexo data in the first half of 2018.

TODAY'S FREE FLY STORIES

TSE

Trinseo

$81.05

-0.3 (-0.37%)

16:44
02/19/18
02/19
16:44
02/19/18
16:44
Earnings
Trinseo reports Q4 adjusted EPS $2.14, consensus $2.06 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

XOM

Exxon Mobil

$76.54

0.33 (0.43%)

16:37
02/19/18
02/19
16:37
02/19/18
16:37
Periodicals
Exxon Mobil acquires 2.5% stake in BTC oil pipeline, Reuters reports »

Exxon Mobil has acquired…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$183.68

-3.77 (-2.01%)

, TCEHY

Tencent

$58.22

-0.4 (-0.68%)

16:31
02/19/18
02/19
16:31
02/19/18
16:31
Periodicals
Alibaba, Tencent on $10B retail battle, Reuters reports »

Alibaba (BABA) and…

BABA

Alibaba

$183.68

-3.77 (-2.01%)

TCEHY

Tencent

$58.22

-0.4 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

DDAIF

Daimler AG

$90.29

0.37 (0.41%)

16:27
02/19/18
02/19
16:27
02/19/18
16:27
Periodicals
Mercedes-Benz cars' software designed to pass emissions test, Bloomberg reports »

U.S. investigators…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$172.43

-0.56 (-0.32%)

16:18
02/19/18
02/19
16:18
02/19/18
16:18
Periodicals
Apple iPhone losing out to Chinese devices in Asia, WSJ reports »

Apple's iPhone X…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

BLK

BlackRock

$541.10

0.45 (0.08%)

16:13
02/19/18
02/19
16:13
02/19/18
16:13
Periodicals
BlackRock upgrades outlook for stocks on earnings momentum, Reuters says »

BlackRock upgraded its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 01

    Mar

  • 06

    Mar

  • 07

    Mar

  • 23

    Apr

FB

Facebook

$177.36

-2.6 (-1.44%)

16:06
02/19/18
02/19
16:06
02/19/18
16:06
Periodicals
Facebook increasing security team size following Russia indictment, Axios says »

Facebook reiterated it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 07

    Mar

  • 18

    Mar

SNHY

Sun Hydraulics

$55.48

-0.74 (-1.32%)

16:02
02/19/18
02/19
16:02
02/19/18
16:02
Hot Stocks
Sun Hydraulics announces acquisition of Faster Group »

Sun Hydraulics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

CCL

Carnival

$69.50

-0.1 (-0.14%)

15:59
02/19/18
02/19
15:59
02/19/18
15:59
Hot Stocks
Carnival Fascination resumes year-round service from San Juan »

Carnival Fascination…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

LUV

Southwest

$58.27

0.09 (0.15%)

15:58
02/19/18
02/19
15:58
02/19/18
15:58
Hot Stocks
Southwest Cargo team to begin shipping internationally in spring 2018 »

Southwest Airlines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.16

-0.03 (-0.03%)

15:55
02/19/18
02/19
15:55
02/19/18
15:55
Hot Stocks
PPG appoints senior business director, mobility »

PPG announced that Ranju…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

15:51
02/19/18
02/19
15:51
02/19/18
15:51
Hot Stocks
Cubic announces semiannual dividend »

Cubic announced that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Jun

CREE

Cree

$36.71

0.21 (0.58%)

15:48
02/19/18
02/19
15:48
02/19/18
15:48
Hot Stocks
Cree names Thomas Wessel as senior vice president of Global Sales and Marketing »

Cree announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

DB

Deutsche Bank

$16.08

-0.03 (-0.19%)

13:59
02/19/18
02/19
13:59
02/19/18
13:59
Upgrade
Deutsche Bank rating change at BofA/Merrill »

Deutsche Bank upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

MNLO

Menlo Therapeutics

$34.88

-0.44 (-1.25%)

13:59
02/19/18
02/19
13:59
02/19/18
13:59
Initiation
Menlo Therapeutics initiated at Guggenheim »

Menlo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHPG

Shire

$134.06

-1.24 (-0.92%)

13:58
02/19/18
02/19
13:58
02/19/18
13:58
Downgrade
Shire rating change at JPMorgan »

Shire downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 23

    Mar

  • 25

    Mar

CVR

Chicago Rivet & Machine

$31.62

-0.0725 (-0.23%)

13:48
02/19/18
02/19
13:48
02/19/18
13:48
Hot Stocks
Chicago Rivet & Machine announces increase in quarterly cash dividend »

On February 19, 2018 the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBL

Noble Energy

$26.28

-0.09 (-0.34%)

13:46
02/19/18
02/19
13:46
02/19/18
13:46
Hot Stocks
Noble announces execution of gas sales agreements for export of gas to Egypt »

Noble Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

TOT

Total

$57.13

0.29 (0.51%)

13:43
02/19/18
02/19
13:43
02/19/18
13:43
Hot Stocks
Total signs definitive agreements with Borealis, NOVA Chemicals to form JV »

Total, Borealis and NOVA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYY

Sysco

$60.00

0.63 (1.06%)

13:39
02/19/18
02/19
13:39
02/19/18
13:39
Hot Stocks
Sysco acquires Doerle Food Services »

Sysco announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 30

    May

SBGI

Sinclair Broadcast

$36.30

-0.95 (-2.55%)

, CMCSA

Comcast

$39.79

-0.29 (-0.72%)

13:36
02/19/18
02/19
13:36
02/19/18
13:36
Hot Stocks
Sinclair announces renewals of NBC affiliation agreements »

Sinclair Broadcast (SBGI)…

SBGI

Sinclair Broadcast

$36.30

-0.95 (-2.55%)

CMCSA

Comcast

$39.79

-0.29 (-0.72%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

III

Information Services

$4.24

-0.02 (-0.47%)

13:33
02/19/18
02/19
13:33
02/19/18
13:33
Hot Stocks
Information Services releases first client-facing mobile app »

Information Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 29

    Mar

  • 12

    Apr

CAT

Caterpillar

$156.29

-3.69 (-2.31%)

13:24
02/19/18
02/19
13:24
02/19/18
13:24
Hot Stocks
Tony Fassino appointed vice president of Caterpillar's BCP division »

Caterpillar announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.49

-0.16 (-0.16%)

13:22
02/19/18
02/19
13:22
02/19/18
13:22
Hot Stocks
Celanese CFO Chris Jensen steps down, Scott Richardson to succeed »

Celanese announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

WOR

Worthington

$46.70

0.57 (1.24%)

, JPM

JPMorgan

$114.68

-0.83 (-0.72%)

13:18
02/19/18
02/19
13:18
02/19/18
13:18
Hot Stocks
Worthington extends existing $500M revolving credit facility »

Worthington Industries…

WOR

Worthington

$46.70

0.57 (1.24%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

PNC

PNC Financial

$159.08

-0.78 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 25

    Feb

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 13

    Apr

  • 13

    Apr

  • 30

    May

  • 13

    Jul

  • 14

    Jul

  • 12

    Oct

  • 12

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.